

**ALAN RICHARD TALL, M.D.**



October 2006

**Personal data:**

Birthplace: Wollongong, NSW, Australia  
Birthdate: April 6, 1947  
Nationality: U.S. Citizen

Home Address: 254 Wilson Drive/P.O. Box 104  
Cresskill, New Jersey 07626  
(201) 568-6206

Business Address: Division of Molecular Medicine, Department of Medicine  
Columbia University Medical Center  
630 West 168th Street  
P&S 8-401  
New York, New York 10032  
Tel.: (212) 305-9418 Fax: (212) 305-5052  
E-mail: art1@columbia.edu

**Appointments & Education:**

2005- Present	Professor of Physiology & Cellular Biophysics
1997- Present	Director, Specialized Center of Research (SCOR) in Molecular Medicine and Atherosclerosis, Columbia University
1996- Present	Tilden Weger Bieler Professor of Medicine, Columbia University
1991- 1996	Director, Specialized Center of Research (SCOR) in Atherosclerosis, Columbia University
1990- Present	Chief, Division of Molecular, Department of Medicine, Columbia University
1989 - Present	Professor of Medicine, Columbia University
1989 - Present	Attending Physician, Presbyterian Hospital
1982-1989	Associate Attending Physician, Presbyterian Hospital

## Alan Richard Tall

1982-1989 Associate Professor of Medicine, Columbia University  
1978-1981 Assistant Attending Physician, Presbyterian Hospital, New York  
1978-1981 Assistant Professor of Medicine, Columbia University, College of Physicians & Surgeons, New York  
1977 Assistant Professor of Medicine, Boston University School of Medicine, Boston, MA  
1975-1976 Chief Resident, Medical Service, Boston City Hospital, Boston, MA  
1974-1975 Gastroenterology Fellow, University Hospital, Boston, MA  
1974 Senior Resident, Medical Service, Boston City Hospital, Boston, MA  
1971-72 Resident, Royal Prince Alfred Hospital, Sydney, Australia  
1970 M.B., B.S. (honors) University of Sydney, Sydney, Australia

### **Board Certification:**

1976 American Board of Internal Medicine

### **Honors:**

2000-2005 Selection Committee and Grant Recipient, Bristol-Myers Squibb Pharmaceutical Research Institute, Award for Distinguished Achievement in Metabolic Research  
1999 George Lyman Duff Memorial Lecturer, American Heart Association  
1999 Dean's Distinguished Lecturer in the Clinical Sciences, Columbia University

### **Professional Societies/Committees:**

1999-2004 Research Committee, American Heart Association  
1995-2000 Board of Scientific Counselors, NHLBI  
1994-1999 Page Award Committee, AHA; Chairman, (1996-1997)  
1992-2002 Advisory Board to Gladstone Research Foundation, UCSF  
1989 Association of American Physicians  
1987-1989 Executive Committee, Arteriosclerosis Council, American Heart Association  
1985-1986 Program Committee, American Heart Association  
1983-1987 Member, Metabolism Study Section, NIH

### **Editorial Boards:**

2002-2007 Associate Editor, Journal of Clinical Investigation  
1988-1993; 1997-2002 Journal of Biological Chemistry  
1987-1993; 1997-2002 Journal of Clinical Investigation  
1985-Present Journal of Lipid Research  
2001-Present Arteriosclerosis, Thrombosis and Vascular Biology

### **Meetings:**

2001 Co-Chair, Gordon Research Conference in Atherosclerosis  
2000 Chair, Kern Aspen Lipid Conference  
1996 Chairman, Combined AHA Conference of Arteriosclerosis, Thrombosis

## Alan Richard Tall

1994 Councils and Vascular Biology Working Group  
Chairman, Gordon Conference in Lipid Metabolism  
1992 Chairman, AHA Conference on HDL

### Departmental Activities:

1997-1999 Tenure Review Advisory Committee, Columbia University  
1993-1995 Committee on Appointments and Promotions, Columbia University;  
Chairman, 1995.  
1993-1995 Director, Combined Clinics of the Department of Medicine, Columbia  
University  
1982-1989 Chairman, Gastroenterology Section, Abnormal Human  
Biology, Columbia University (Gastroenterology course for medical students)

### PUBLICATIONS

1. Lam KC, **Tall AR**, Goldstein GB, and Mistilis SP. Role of a false neurotransmitter, octopamine, in the pathogenesis of hepatic and renal encephalopathy. *Scand. J. Gastroenterol.* 8:465-472, 1973.
2. **Tall AR** and Mistilis SP. Studies on mefenamic acid: I. Gastrointestinal blood loss. II. Absorption and excretion of a new formulation. *J. Intl. Med. Res.* 3:176-182, 1974.
3. Mistilis SP, Goren R, **Tall AR** and Hickie JR. Plasma lipids in extra hepatic biliary obstruction. *Australian and New Zealand J. Med.* 5:540-543, 1975.
4. **Tall AR**, Small DM Shipley GG, and Lees R.S. Apoprotein stability and lipid protein interactions in human plasma high density lipoproteins. *Proc. Natl. Acad. Sci. USA* 72:4940-4942, 1975.
5. **Tall AR**, Shipley GG and Small DM. Conformational and thermodynamic properties of apoprotein A-I of human high density lipoproteins. *J. Biol. Chem.* 251:3749-3755, 1976.
6. **Tall AR**, Mistilis SP and Shields RJ. Cholesterol and phospholipid: Influence of body weight on the output of lipids in mesenteric lymph. *Australian and New Zealand J. Med.* 7:151-155, 1977.
7. Deckelbaum RJ, **Tall AR** and Small DM. The interaction of cholesterol ester and triglyceride in human plasma very low density lipoproteins. *J. Lipid Res.* 18:164-168, 1977.
8. **Tall AR**, Deckelbaum RJ, Small DM and Shipley GG. Thermal behavior of human plasma high density lipoproteins. *Biochim. Biophys. Acta* 487:145-153, 1977.
9. **Tall AR** and Small DM. Solubilization of phospholipid membranes by human plasma high density lipoproteins. *Nature* 265:163-164, 1977.
10. **Tall AR**, Deckelbaum RJ, Small DM and Shipley GG. Structure and thermodynamic properties of high density lipoprotein recombinants. *J. Biol. Chem.* 252:4701-4711, 1977.
11. **Tall AR**, Atkinson D, Small DM and Mahley, R.: Characterization of the lipoproteins of Atherosclerotic swine. *J. Biol. Chem.* 252:7288-7293, 1977.

## Alan Richard Tall

12. Fallon JA, **Tall AR**, Janis MG and Brauer MJ. Oxcallin-induced granulocytopenia Acta Haematol. 59:163-170, 1978.
13. **Tall AR**, Hogan V, Askinazi LA and Small DM. Interaction of plasma high density lipoproteins with dimyristoyl lecithin multilamellar liposomes. Biochemistry 17:322-326, 1978.
14. Green PHR, Tall AR and Glickman RM. Rat intestine secretes discoidal high density lipoproteins. J. Clin. Invest. 61:528-534, 1978.
15. Atkinson D, **Tall AR**, Small DM and Mahley RW. Structural organization of the lipoprotein HDL from atherosclerotic swine. Structural features relating the particle surface and core. Biochemistry 17:3930-3933, 1978.
16. **Tall AR**, Small DM and Lees RS. Interaction of collagen with the lipids of tendon xanthomata. J. Clin. Invest. 62:836-846, 1978.
17. **Tall AR**, Rudel LL, Small DM and Atkinson D. Studies on the structure of low density lipoproteins isolated from Macac Fascicularis fed on atherogenic diet. J. Clin. Invest. 62:1354-1363, 1978.
18. Glickman RM, Green PHR, Lees R and **Tall AR**. Apoprotein A-I synthesis occurs in normal intestinal mucosa and in Tangier disease. New Engl. J. Med. 299:1424-1427, 1978.
19. **Tall AR** and Small DM. Plasma high-density lipoproteins. New Engl. J. Med. 299:1232-1236, 1978.
20. **Tall AR** and Lange Y. Interaction of cholesterol, phospholipid and apoprotein in high density lipoprotein recombinants. Biochim. Biophys. Acta 513:185-197, 1978.
21. **Tall AR** and Lange Y. Incorporation of cholesterol into high density lipoprotein recombinants. Biochem. Biophys. Res. Commun. 80:206-212, 1978.
22. Small DM, Atkinson D, Redgrave T, Shipley GG and **Tall AR**. A biophysical approach to cholesterol transport from tissues to bile. Vol.4 in Hepatology- Research and Clinical Issues, Gallstones, Plenum Press, (New York), pp. 113-129, 1979.
23. Chobanian J, **Tall AR** and Brecher PB. Interaction between unilamellar egg yolk lecithin vesicles and human high density lipoprotein. Biochemistry 18:180-187, 1979.
24. Green PHR, Glickman RM, Saudek CD, Blum CR and **Tall AR**. Human intestinal lipoproteins. Studies in chyluric subjects. J.Clin.Invest. 64:233-242, 1979.
25. **Tall AR**, Green PHR, Glickman RM and Riley JW. Metabolic fate of chylomicron phospholipids and apoproteins in the rat. J. Clin. Invest. 64:977-989, 1979.
26. Green PHR and **Tall AR**. Drugs, alcohol and malabsorption. Amer. J. Med. 67:1066-1079, 1979.

## Alan Richard Tall

27. **Tall AR** and Robinson LA. Absence of liquid crystalline transitions of cholesterol esters in reconstituted low density lipoproteins. *FEBS Letter* 107:222-226, 1979.
28. **Tall AR** and Small DM. Body cholesterol removal: Role of plasma high density lipoproteins. *Advances in Lipid Res.* 17:1-51, 1980.
29. Brasitus TA, **Tall AR** and Schachter D. Thermotropic transitions in rat intestinal plasma membranes studied by differential scanning calorimetry and fluorescence polarization. *Biochemistry* 19:1256-1261, 1980.
30. **Tall AR**. Studies on the transfer of phosphatidylcholine from unilamellar vesicles into plasma high density lipoproteins in the rat. *J. Lipid. Res.* 21:354-363, 1980.
31. **Tall AR**, Abreu, E, Glickman RM, Green PHR and Riley JW. Products of delipidation of intestinal chylomicrons with diethyl ether. *Atherosclerosis* 36:223-239, 1980.
32. **Tall AR**. Structure of plasma lipoproteins - view from calorimetric studies. *Ann. NY Acad. Sci.* 348:335-351, 1980.
33. Riley JW, Glickman RM, Green PHR and **Tall AR**. The effect of chronic cholesterol feeding on intestinal lipoproteins in the rat. *J. Lipid Res.* 21:942-952, 1980.
34. **Tall AR**, Puppione DL, Kunitake ST, Atkinson D, Small DM and Waugh D. Organization of the core lipids of high density lipoproteins in the lactating bovine. *J. Biol. Chem.* 256:170-174, 1981.
35. **Tall AR** and Green PHR. Incorporation of phosphatidylcholine into spherical and discoidal lipoproteins during incubation of egg phosphatidylcholine vesicles with isolated high density lipoproteins or with plasma. *J. Biol. Chem.* 256:2035-2044, 1981.
36. Bearnot HR, Glickman RM, Weinberg L, Green PHR and **Tall AR**. Effect of biliary diversion on rat mesenteric lymph apoA-I and HDL. *J. Clin. Invest.* 69:210-217, 1982.
37. **Tall AR**, Blum CB, Forester GP and Nelson C. Changes in the distribution and composition of plasma high density lipoproteins after ingestion of fat. *J. Biol. Chem.* 257:198-207, 1982.
38. Fleisher LN, **Tall AR**, Witte LD, Miller RW and Cannon PJ. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. *J. Biol. Chem.* 257:6653-6655, 1982.
39. Blum CB, Deckelbaum RJ, Witte LD, **Tall AR** and Cornicelli J. The role of the apoE containing lipoproteins in abetalipoproteinemia. *J. Clin. Invest.* 70:1157-1169, 1982.
40. **Tall AR** and Robinson L. Facilitation of phosphatidylcholine transfer into plasma high density lipoproteins by an apoprotein in the density 1.20-1.26 g/ml fraction of plasma. *J. Lipid Res.* 24:277-289, 1983.

## Alan Richard Tall

41. Forester GP, **Tall AR**, Bisgaier, CL and Glickman RM. Rat intestine secretes spherical high density lipoproteins. *J. Biol. Chem.* 258:5938-5943, 1983.
42. **Tall AR**, Blum CB and Grundy SM. Incorporation of orally administered radioactive phospholipid into subclasses of HDL. *Am. J. Physiol.* 244:E513-E516, 1983.
43. Fleisher LN, **Tall AR**, Witte LD and Cannon PJ. Effects of high density lipoproteins and the apoprotein of high density lipoprotein on prostacyclin synthesis by endothelial cells. *Advances in Prostaglandin Thromboxane and Leukotriene Research Vol. II*:475-480, 1983.
44. **Tall AR**, Abreu E and Shuman JS. Separation of plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein. *J. Biol.Chem.* 258:2174-2186, 1983.
45. Goldberg CS, **Tall AR** and Krumholz S. Acute inhibition of hepatic lipase and increase in plasma lipoproteins after alcohol intake. *J. Lipid Res.* 25:714-720, 1984.
46. Pomerantz K, **Tall AR**, Feinmark SJ and Cannon P. Stimulation of vascular smooth muscle prostacyclin and prostaglandin E2 synthesis by plasma high and low density lipoproteins. *Circulation Res.* 54:554-565, 1984.
47. **Tall AR**, Sammett D, Vita G, Deckelbaum RJ and Olivecrona T. Lipoprotein lipase enhances the cholesteryl ester transfer protein-mediated transfer of cholesteryl esters from high density lipoproteins to very low density lipoproteins. *J. Biol. Chem.* 259:9587-9594, 1984.
48. Tabas I, and **Tall AR**. Mechanism of the association of HDL<sub>3</sub> with endothelial cells, smooth muscle cells, and fibroblasts. *J. Biol. Chem.* 259:13897-13905, 1984.
49. Fleisher LN, **Tall AR**, Witte LD and Cannon PJ. Plasma lipoproteins and prostglandin biosynthesis. IN *Biological Protection with Prostaglandins*, CRC Press, Ed. M. Cohen, 131-144, 1985.
50. Tabas I, Weiland D, and **Tall AR**. Unmodified low density lipoprotein causes cholesteryl ester accumulation in J774 macrophages. *Proc. Natl. Acad. Sci. USA* 82:416-420, 1985.
51. **Tall AR**, Krumholz S, Olivecrona T and Deckelbaum RJ. Plasma phospholipid transfer protein enhances transfer and exchange of phosphatidycholine between VLDL and HDL during lipolysis. *J. Lipid Res.* 26:842-852, 1985.
52. Pomerantz K, Fleisher L, **Tall AR** and Cannon PJ. Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: Relationship to prostaglandin I2 synthesis. *J. Lipid Res.* 26:1269-1276, 1985.
53. Sammett, D and **Tall AR**. Mechanisms of enhancement of cholesteryl ester transfer protein activity by lipolysis. *J. Biol. Chem.* 260:6687-6697, 1985.
54. **Tall AR**, Tabas I and Williams KJ. Lipoprotein-liposome interactions. IN *Methods in Enzymology*.

## Alan Richard Tall

- The Plasma Lipoproteins (eds. J. Albers and J. Segrest)128:647-656, 1986.
55. **Tall AR.** Metabolism of postprandial lipoproteins in *Methods in Enzymology. The Plasma Lipoproteins* (eds. J. Albers and J. Segrest) 129:469-482, 1986.
  56. **Tall AR, Sammett D and Granot E.** Mechanisms of enhancement of cholesteryl ester transfer from high density lipoproteins to apoB-containing lipoproteins during alimentary lipemia. *J. Clin. Invest.* 77:1163-1172, 1986.
  57. **Tabas I, Weiland D and Tall AR.** Inhibition of acylCoA:cholesterol acyltransferase enhances LDL receptor and HMG CoA reductase down-regulation and prevents LDL-induced cholesterol accumulation in J774 macrophages. *J. Biol. Chem.* 261:3147-3155, 1986.
  58. **Tall AR.** Plasma lipid transfer proteins. *J. Lipid Res.* 27:361-368, 1986.
  59. **Williams KJ, Tall AR, Tabas I and Blum CB.** Recognition of vesicular lipoproteins by the apolipoprotein B,E receptor of cultured fibroblasts. *J. Lipid Res.* 27:892-900, 1986.
  60. **Tall AR, Granot E, Tabas I, Williams KJ, Brocia R, Hesler C and Denke M.** Accelerated transfer of cholesteryl esters in dyslipidemic plasma. *J.Clin. Invest.* 79:1217-1225, 1987.
  61. **Hesler C, Swenson T and Tall AR.** Purification and characterization of a human plasma cholesteryl ester transfer protein. *J. Biol. Chem.* 262:2275-2282, 1987.
  62. **Tabas I, Boykow G and Tall AR.** Foam cell-forming J774 macrophages have markedly elevated LDL-induced cholesterol esterification activity compared to mouse peritoneal macrophages despite similar LDL receptor activity. *J. Clin. Invest.*79:418-426, 1987.
  63. **Granot E, Tabas I and Tall AR.** Human plasma cholesteryl ester transfer protein enhances the uptake of HDL cholesteryl esters by cultured hepatoma (HepG2) cells. *J. Biol. Chem.* 262:3482-3487, 1987.
  64. **Williams KJ, Tall AR, Bisgaier C and Brocia R.** Phospholipid liposomes acquire apolipoprotein E in atherogenic plasma and block cholesterol-loading of cultured macrophages. *J. Clin. Invest.* 79:1466-1472, 1987.
  65. **Tabas I, Boykow GC, Weiland DA and Tall AR.** The J774 macrophage model of native LDL-induced foam cell formation in Cardiovascular Disease: Molecular and Cellular Mechanisms, Prevention, and Treatment (Gallo, L., ed.), Plenum, New York, pp. 121-132, 1987.
  66. **Swenson T, Simmons J, Hesler C, Bisgaier C and Tall AR.** Cholesteryl ester transfer protein is secreted by Hep G2 cells and contains asparagine-linked carbohydrate and sialic acid. *J. Biol. Chem.* 262:16271-16274, 1987.
  67. **Tall AR, Swenson T, Hesler, C, and Granot, E.** Mechanisms of facilitated lipid transfer mediated by plasma lipid transfer proteins. in *Plasma Lipoproteins.* Ed. A.M. Gotto, 14:277-298, 1987.

## Alan Richard Tall

68. Swenson T, Brocia R and **Tall AR**. Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids. *J. Biol. Chem.* 263:5150-5157, 1988.
69. Hesler CB, Milne RW, Swenson TL, Weech PK, Marcel YL and **Tall AR**. Monoclonal antibodies to the Mr 74,000 cholesteryl ester transfer protein neutralize all of the cholesteryl ester and triglyceride transfer activities in human plasma. *J. Biol. Chem.* 263:5020-5023, 1988.
70. Williams KJ and **Tall AR**. Interaction of liposomes with lipoprotein: relevance to drug delivery systems and to the treatment of atherosclerosis. in *Liposomes as Drug Carriers. Recent Trends and Progress*. Ed. G. Gregoriadis 93-111, 1988.
71. Aviram M, Williams KJ, McIntosh RA, Carpentier Y, **Tall AR** and Deckelbaum RJ. Intralipid infusion abolishes the ability of human serum to cholesterol-load cultured macrophages. *Arteriosclerosis*, 9:67-75, 1989.
72. Yen FY, Deckelbaum RJ, Mann CJ, Marcel YL, Milne RW and **Tall AR**. Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody: Effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma. *J. Clin. Invest.* 83:2018-2024, 1989.
73. Swenson T, Hesler CB, Brown ML, Quinet E, Trotta PP, Haslanger MF, Gaeta FC, Marcel VL, Milne RW and **Tall AR**. Mechanism of cholesteryl ester transfer protein inhibition by a neutralizing monoclonal antibody and mapping of the monoclonal antibody epitope. *J. Biol. Chem.*, 264:14318-14326, 1989.
74. Whitlock ME, Swenson TL, Ramakrishnan R, Leonard MT, Marcel YL, Milne RW, and **Tall AR**. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit: Effects on lipoprotein composition and HDL cholesteryl ester metabolism. *J. Clin. Invest.* 84:129-137, 1989.
75. Bisgaier CL, Siebenkas MV, Hesler CB, Swenson TL, Blum CB, Marcel YL, Milne RW, Glickman RM and **Tall AR**. Effect of a neutralizing monoclonal antibody to cholesteryl ester transfer protein on the redistribution of apolipoproteins A-IV and E among human lipoproteins, *J. Lipid Res.*, 30:1025-1031, 1989.
76. Hesler CB, Brown ML, Feuer DS, Marcel YL, Milne RW and **Tall AR**. Structure-function analysis of plasma cholesteryl ester transfer protein by protease digestion and expression of cDNA fragments in *E. coli*. *J. Biol. Chem.* 30:1025-1032, 1989.
77. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H, Takeda R and **Tall AR**. Molecular basis of lipid transfer protein deficiency in a family with increased high density lipoproteins. *Nature*, 342:448-451, 1989.
78. Marcel YL, Czarnecka H, McPherson R, Hesler CB, Milne RW and **Tall AR**. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipidemic subjects. *J. Clin. Invest.* 85:10-17, 1990.



## Alan Richard Tall

79. Quinet E, Agellon L, Marcel Y, Milne R, Kroon P and **Tall AR**. Atherogenic diet increases cholesteryl ester transfer protein mRNA in rabbit liver. *J. Clin. Invest.* 85:357-363, 1990.
80. **Tall AR**. Plasma high density lipoproteins - metabolism and relationship to atherogenesis. *J. Clin. Invest.* 86:379-384, 1990.
81. Agellon L, Quinet E, Gillette T, Drayna D, Brown M and **Tall AR**. Organization of the human cholesteryl ester transfer protein gene. *Biochemistry*, 29:1372-1376, 1990.
82. Tabas I, Chen L, Clader JW, McPhail AT, Burnett DA, Bartner P, Das PR, Pramanik BN, Puar MS, Feinmark SJ, Zipkin RE, Boykow G, Vita G and **Tall AR**. Rabbit and human liver contain a novel pentacyclic triterpene ester with acyl-CoA:cholesteryl acyltransferase inhibitory activity. *J. Biol. Chem.* 265:8042-8051, 1990.
83. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H and **Tall AR**. Increased high density lipoprotein caused by a common cholesteryl ester transfer protein gene mutation. *N. Engl. J. Med.*, 323:1234-1238, 1990.
84. Brown ML, Hesler C and **Tall AR**. Plasma enzymes and transfer proteins in cholesterol metabolism. *Current Opinion in Lipidology* 1:122-127, 1990.
85. Jiang X, Moulin P, Quinet E, Goldberg IJ, Yacoub LK, Agellon LB, Compton D, Polokoff R and **Tall AR**. Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. *J. Biol. Chem.*, 266:4631-4639, 1991.
86. Quinet E, **Tall AR**, Ramakrishnan R and Rudel L. Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. *J. Clin. Invest.* 87:1559-1566, 1991.
87. Agellon LB, Walsh A, Hayek T, Moulin P, Jiang X, Shelanski SA, Breslow JL and **Tall AR**. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. *J. Biol. Chem.* 266:10796-10801, 1991.
88. Wang S, Deng L, Brown ML, Agellon LB and **Tall AR**. Structure-function studies of human cholesteryl ester transfer protein by linker insertion scanning mutagenesis. *Biochemistry*, 30:3484-3490, 1991.
89. Koizumi J, Inazu A, Kunimas Y, Ichiro K, Uno Y, Kajinami K, Miyamoto S, Moulin P, **Tall AR**, Mabuchi H and Takeda R. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. *Atherosclerosis* 90:189-196, 1991.
90. McPherson R, Mann CJ, **Tall AR**, Hogue M, Martin L, Milne RW and Marcel YL. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia: Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. *Arterioscl. Thromb.* 11:797-804, 1991.

## Alan Richard Tall

91. McPherson R, Hogue M, Milne RW, **Tall AR** and Marcel YL. Increase in plasma cholesteryl ester transfer protein during probucol treatment: Relation to changes in high density lipoprotein composition. *Arterioscl. Thromb.* 11:476-481,1991.
92. Bisgaier CL, Siebenkas MV, Brown ML, Inazu A, Koizumi J, Mabuchi H and **Tall AR**. Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin. *J. Lipid Res.* 32:21-33, 1991.
93. Inazu A, Quinet EM, Wang S, Brown ML, Stevenson S, Barr ML, Moulin P and **Tall AR**. Alternative splicing of the mRNA encoding the human cholesteryl ester transfer protein. *Biochemistry*, 31:2352-2358, 1992.
94. Hayek T, Chajek-Shaul T, Walsh A, Agellon LB, Moulin P, **Tall AR** and Breslow JL. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of HDL cholesterol levels. *J. Clin. Invest.* 90:505-510, 1992.
95. Wang S, Deng L, Milne RW and **Tall AR**. Identification of a sequence within the C-terminal 26 amino acids of cholesteryl ester transfer protein responsible for binding a neutralizing monoclonal antibody and necessary for neutral lipid transfer activity. *J. Biol. Chem.* 267:17487-17490, 1992.
96. **Tall AR**. Metabolic and genetic control of HDL cholesterol levels. *J. Int. Med.* 231:661-668, 1992.
97. Jiang XC, Agellon LB, Walsh A, Breslow JL and **Tall AR**. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice: Dependence on natural flanking sequences. *J. Clin. Invest.* 90:1290-1295, 1992.
98. Agellon LB, Zhang P, Christie B, Mendelsohn L and **Tall AR**. The CCAAT/Enhancer binding protein transactivates the human cholesteryl ester transfer gene promoter. *J. Biol. Chem.* 267:22336-22339, 1992.
99. Moulin P, Appel GB, Ginsberg HN and **Tall AR**. Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. *J. Lipid Res.* 33:1817-1822, 1992.
100. Wang S, Wang X, Deng L, Rassart E, Milne RW and **Tall AR**. Point mutagenesis of carboxyl-terminal amino acids of cholesteryl ester transfer protein-opposite faces of an amphipathic helix important for cholesteryl ester transfer or for binding neutralizing antibody. *J. Biol. Chem.* 268:1955-1959, 1993.
101. Martin LJ, Connelly PW, Nanchoo D, Wood N, Xhang ZJ, Maguire G, Quinet E, **Tall AR**, Marcel YL and McPherson R. Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in men: relationship to apolipoprotein E genotype. *J. Lipid Res.* 34:437-446, 1993.

## Alan Richard Tall

102. Stevenson SC, Wang S, Deng L and **Tall AR**. Human plasma cholesteryl ester transfer protein consists of a mixture of two forms reflecting variable glycosylation at Asparagine 341. *Biochemistry*, 32:5121-5126, 1993.
103. Quinet E, Yang TP, Marinos C and **Tall AR**. Inhibition of the cellular secretion of cholesteryl ester transfer protein by a variant protein formed by alternative splicing of mRNA. *J. Biol. Chem.* 268:16891-16894, 1993.
104. Hayek T, Azrolan N, Verdery RB, Walsh A, Chajek-Shaul T, Agellon LB, **Tall AR** and Breslow JL. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. *J. Clin. Invest.* 92:1143-1152, 1993.
105. Seip RL, Moulin P, Cocke T, **Tall AR**, Kohrt WM, Mankowitz K, Semenkovich CF, Ostlund R and Schonfeld G. Exercise training decreases plasma cholesteryl ester transfer protein. *Arterioscler. Thromb.* 13:1359-1367, 1993.
106. Takahashi K, Jiang, X-C, Sakai N, Yamashita S, Hirano K, Bujo H, Yamazaki H, Kusunoki J, Miura T, Kussie P, Matsuzawa Y, Saito Y and **Tall AR**. A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoprotein. *J. Clin. Invest.* 92:2060-2064, 1993.
107. Jiang, X-C, Masucci-Magoulas L, Mar J, Lin M, Walsh A, Breslow JL and **Tall AR**. Down-regulation of LDL receptor mRNA in human cholesteryl ester transfer protein transgenic mice: Mechanism to explain accumulation of lipoprotein B particles. *J. Biol. Chem.* 268:27406-27412, 1993.
108. Silliman K, **Tall AR**, Kretchmer N and Forte TM. Unusual high-density lipoprotein subclass distribution during late pregnancy. *Metabolism*, 42:1592-1599, 1993.
109. Ginsberg HN, Karmally W, Siddiqui M, Holleran S, **Tall AR**, Rumsey SC, Deckelbaum RJ, Blaner WS and Ramakrishnan R. A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men. *Arterioscle. Thromb.* 14:576-586, 1994.
110. Moulin P, Cheung MC, Bruce C, Zhong S, Cocke T, Richardson H and **Tall AR**. Gender effects on the distribution of the cholesteryl ester transfer protein in apolipoprotein A-I defined lipoprotein subpopulations. *J. Lipid Res.* 35:793-802, 1994.
111. Inazu A, Jiang X-C, Haraki T, Kamon N, Koizumi J, Mabuchi H, Takeda R, Takata K, Moriyama Y, Doi M and **Tall AR**. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. *J. Clin. Invest.* 94:1872-1882, 1994.
112. Zhong S, Goldberg IJ, Bruce C, Rubin E, Breslow J and **Tall AR**. Human apoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and

## Alan Richard Tall

- cholesteryl ester transfer protein in transgenic mice. *J. Clin. Invest.* 94:2457-2467, 1994.
113. Weinberg RB, Cook VR, Jones JB, Kussie P and **Tall AR**. Inter-facial properties of recombinant human cholesterol ester transfer protein. *J. Biol. Chem.* 269:29588-29591, 1994.
  114. Wang S, Kussie P, Deng L and **Tall AR**. Defective binding of neutral lipids by a carboxyl terminal deletion mutant of cholesteryl ester transfer protein: evidence for a C-terminal cholesteryl ester binding site essential for neutral lipid transfer activity. *J. Biol. Chem.* 270:612-618, 1995.
  115. **Tall AR**. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies. *J. Int. Med.* 237:5-12, 1995.
  116. Tato F, Vega GL, **Tall AR** and Grundy SM. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. *Arterioscler. Thromb. Vasc. Biol.* 15:112-120, 1995.
  117. Ginsberg HN, Karmally W, Siddiqui M, Holleran S, **Tall AR**, Blaner WS and Ramakrishnan R. Increases in dietary cholesterol are associated with modest increases in both LDL and HDL cholesterol in healthy young women. *Arterioscler. Thromb. Vasc. Biol.* 15:169-178, 1995.
  118. Masucci-Magoulas L, Moulin P, Jiang X-C, Richardson H, Walsh A., Breslow JL and **Tall AR**. Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased HDL following lipopolysaccharide administration in human CETP transgenic mice. *J.Clin.Invest.* 95:1587-1594, 1995.
  119. **Tall AR**. Plasma lipid transfer proteins. *Annu. Rev. Biochem.* 64:235-257, 1995.
  120. Bruce C, Davidson WS, Kussie P, Lund-Katz S, Phillips MC, Ghosh R and **Tall AR**. Molecular determinants of plasma cholesteryl ester transfer protein binding to high density lipoproteins. *J. Biol. Chem.* 270:11532-11542, 1995.
  121. Jiang X-C, Bruce C, Cocke T, Wang S, Boguski M and **Tall AR**. Point mutagenesis of positively charged amino acids of cholesteryl ester transfer protein: conserved residues within the lipid transfer/lipopolysaccharide binding protein gene family essential for function. *Biochem.* 34:7258-7263, 1995.
  122. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow J.L and **Tall AR**. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. *J. Clin. Invest.* 96:2071-2074, 1995.
  123. Atger V, de la Llera Moya M, Bamberger M, Francone O, Cosgrove P, **Tall AR**, Walsh A, Moatti N and Rothblat G. Cholesterol efflux potential of sera From mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI. *J.Clin.Invet.* 96:2613-2923, 1996.
  124. Zhong S, Sharp DS, Grove JS, Bruce C, Katsuhiko Y, Curb JD and **Tall AR**. Increased coronary heart disease in Japanese-American men with mutations in the cholesteryl Ester transfer protein

## Alan Richard Tall

- gene despite increased HDL levels. *J.Clin.Invest* 97:2917-2923, 1996.
125. Wang N, Tabas I, Winchester R, Ravalli S, Rabbani LE and **Tall AR**. Interleukin 8 is induced by cholesterol loading of macrophages and expressed by macrophage foam cells in human atheroma. *J. Biol. Chem.* 271(15):8837-8842. 1996.
  126. Masucci-Magoulas L, Plump A, Jiang S-C, Walsh A, Breslow JL and **Tall AR**. Profound induction of hepatic cholesteryl ester transfer protein transgene expression in apoE and LDL receptor gene knock-out mice: a novel mechanism signals changes in plasma cholesterol levels. *J.Clin. Invest.* 97: 154-161, 1996.
  127. Yang T-P, Agellon L, Walsh A, Breslow JL, **Tall AR**. Alternative splicing of the human cholesteryl ester transfer protein gene in transgenic mice: exon exclusion modulates gene expression in response to dietary or developmental change. *J. Biol. Chem.* 271:12603-12616, 1996.
  128. Roy P, MacKenzie R, Hiramata T, Jiang X-C, Kussie P, **Tall AR**, Rassart E and Milne R. Structure-function relationships of human cholesteryl ester transfer protein: analysis using monoclonal antibodies. *J. Lipid Res.* 37:22-34, 1996.
  129. Jiang X-C, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow JL and **Tall AR**. Increased pre $\beta$ -high density lipoprotein, apolipoprotein AI and phospholipid in mice expressing the human phospholipid transfer and human apolipoprotein AI transgenes. *J. Clin. Invest.* 98:2373-2380, 1996.
  130. Oliveira HCF, Chouinard RA, Agellon LB, Bruce C, Ma L, Walsh A, Breslow JL and **Tall AR**. Human cholesteryl ester transfer protein gene proximal promoter contains dietary cholesterol positive responsive elements and mediates expression in small intestine and periphery while predominant liver and spleen expression is controlled by 5' distal sequences: cis-acting sequences mapped in transgenic mice. *J. Biol. Chem.* 271:31831-31838, 1996.
  131. Wang N, Weng W, Breslow JL and **Tall AR**. Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. *J. Biol. Chem.* 35:21001-21004, 1996.
  132. McPherson R, Lau P, Kussie P and **Tall AR**. Plasma Kinetics of Cholesteryl Ester Transfer Protein in the Rabbit. *Arterioscl. Thromb. Vasc. Biol.* 17:203-210, 1997.
  133. Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, Serajuddin H, Francone OL, Breslow JL and **Tall AR**. A mouse model with features of familial combined hyperlipidemia. *Science*, 275:391-394, 1997.
  134. Gupta S, Pablo AM, Jiang, X-C, Wang N, **Tall AR** and Schindler C. IFN-gamma Potentiates Atherosclerosis in ApoE Knock-Out Mice. *J. Clin.Invest.* 99:2752-2761,1997.
  135. Plump AS, Azrolan N, Odaka H, Wu L, Jiang X, **Tall AR**, Eisenberg S and Breslow JL. ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-

## Alan Richard Tall

- RNA mechanism of apoA-I up-regulation in heterozygotes. *J. Lipid Res.* 1997.38:1033-1047.
136. Oliveira HCF, Ma L, Milne R, Marcovina SM, Inazu A, Mabuchi H and **Tall AR**. Cholesteryl Ester Transfer Protein Activity Enhances Plasma Cholesteryl Ester Formation. *ATVB* 17:1045-1052, 1997.
137. Ji Y, Jian B, Wang N, Sun Y, Moya Liera M, Phillips MC, Rothblat GH, Swaney JB and **Tall AR**. Scavenger Receptor BI Promotes High Density Lipoprotein-mediated Cellular Cholesterol Efflux. *J. Biol. Chem.* 34:20982-20985, 1997.
138. Bruce C, Sharp DS and **Tall AR**. Increased HDL and Coronary Heart Disease in Hypertriglyceridemic Men with a Common Amino Acid Polymorphism in the Cholesteryl Ester Transfer Protein. *J. Lipid Res.* 39:1071-1078, 1998.
139. Jeong T-S, Schissel SL, Tabas I, Pownall HJ, **Tall AR** and Jiang X-C. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knock-out mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. *J. Clin. Invest.* 101:905-912, 1998.
140. Varban ML, Rinninger F, Wang N, Fairchild-Huntress V, Dunmore JH, Fang Q, Gosselin ML, Dixon KL, Deeds JD, Acton SL, **Tall AR** and Huszar D. Targeted Mutation Reveals a Central Role for SR-BI in Hepatic Selective Uptake of HDL Cholesterol. *Proc. Nat'l Acad. Sci. USA*, 95:4619-4624, 1998. [Editorial, M. Krieger, The "best" of cholesterol the "worst" of cholesterol: a tale of two receptors. *PNAS*, 95: 4077-4080, 1998].
141. Jian B, de la Llera-Moya M, Ji Y, Wang N, Phillips MC, Swaney JB, **Tall AR** and Rothblat G. Scavenger Receptor BI as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. *J. Biol. Chem.*, 273:5599-5506, 1998.
142. Bruce C, Chouinard RA and **Tall AR**. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. *Annu. Rev. Nutr.* 18:297-330, 1998.
143. Chouinard RA, Luo Y, Osborne TF, Walsh A and **Tall AR**. Sterol Regulatory Element Binding protein-1 Activates the Cholesteryl Ester Transfer Protein Gene *in Vivo* but Is Not Required for Sterol Up-regulation of Gene Expression. *J. Biol. Chem.*, 273:22409-22414, 1998.
144. Sehayek E, Ono JG, Shefer S, Nguyen LB, Wang N, Batta AK, Salen G, Smith JD, **Tall AR** and Breslow JL. Biliary cholesterol excretion: A novel mechanism that regulates dietary cholesterol absorption. *Proc. Natl. Acad. Sci.* 95:10194-10199, 1998.
145. Bruce C, Beamer LJ and **Tall AR**. The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein. *Current Opinion Structural Biology*, 4:426-434, 1998.
146. **Tall AR**. An overview of reverse cholesterol transport. *Eur Heart J.*, 19:A31-A35, 1998.

## Alan Richard Tall

147. Wang N, Arai T, Ji Y, Rinninger F and **Tall AR**. Liver-specific overexpression of Scavenger Receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice, *J. Biol.Chem.* 273:32920-32926, 1998.
148. Silver DL, Jiang XC, and **Tall AR**. Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice.Possible role of leptin in stimulation of HDL turnover.*J. Biol Chem.*274:4140-6, 1999.
149. Arai T, Wang N, Bezouevski, Welch C and **Tall AR**. Decreased Atherosclerosis in heterozygous Low Density Lipoprotein Receptor-deficient Mice Expressing the Scavenger Receptor BI Transgene. *J. Biol.Chem.* 274:2366-2371,1999.
150. Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL and **Tall AR**. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. *J Clin Invest.* 103:907-914, 1999.
151. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, and **Tall AR**. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. *Arterioscler Thromb Vasc Biol.* 4:1105-10, 1999.
152. Weng W, Brandenburg NA, Zhong S, Hakias J, Wu L, Jiang X-C, **Tall AR** and Breslow JL. ApoA-II maintains HDL levels in part by inhibition of hepatic lipase. *Studies In apoA-II and hepatic lipase double knockout mice.**J Lipid Res.*6:1064-7, 1999.
153. Collet X, **Tall AR**, Serajuddin H, Guendouzi K, Royer L, Oliveira H, Barbaras R, Jiang X and Francone OL. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I *J Lipid Res.*40:1185-1193, 1999.
154. Rinninger F, Wang N, Ramakrishnan R, Jiang XC and **Tall AR**. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. *Arterioscler Thromb Vasc Biol.* 19:1325-1332, 1999.
155. Lemaitre V, O'Byrne TK, Dalal SS, **Tall AR**, D'Armiento JM. Macrophage-specific expression of human collagenase (MMP-1) in transgenic mice. *Ann N Y Acad Sci.* 1999 Jun 30;878:736-9.
156. Sun Y, Wang N, **Tall AR**. Regulation of adrenal scavenger receptor-BI expression by ACTH and cellular cholesterol pools. *J Lipid Res.* 1999.
157. Arai T, Rinninger F, Varban L, Fairchild-Huntress V, Liang CP, Chen W, Seo T, Deckelbaum R, Huszar D, **Tall AR**. Decreased selective uptake of high density lipoprotein cholesteryl esters in apolipoprotein E knock-out mice. *Proc Natl Acad Sci U S A.* 1999 Oct 12;96(21):12050-5.
158. Ji Y, Wang N, Ramakrishnan R, Sehayek E, Huszar D, Breslow JL, **Tall AR**. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. *J Biol Chem.* 1999 Nov 19;274(47):33398-402.

## Alan Richard Tall

159. Silver DL, Wang N, **Tall AR**. Defective HDL particle uptake in ob/ob hepatocytes causes decreased recycling, degradation, and selective lipid uptake. *J Clin Invest*. 2000 Jan;105(2):151-9.
160. **Tall, A.R.**, Jiang X-C, Luo, Y., Silver, D. 1999 George Lyman Duff Memorial Lecture: Lipid Transfer Proteins, HDL Metabolism, and Atherogenesis. *ATVB* 2000;50(5): 1185-1188.
161. Qin S, Kawano K, Bruce C, Lin M, Bisgaier C, **Tall AR**, Jiang X. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. *J Lipid Res*. 2000 Feb;41(2):269-76.
162. Luo Y, **Tall AR**. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. *J Clin Invest*. 2000 Feb;105(4):513-20.
163. Huszar D, Varban ML, Rinninger F, Feeley R, Arai T, Fairchild-Huntress V, Donovan MJ, **Tall AR**. Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenuated expression of scavenger receptor B1. *Arterioscler Thromb Vasc Biol*. 2000 Apr;20(4):1068-73.
164. Silver DL, Jiang XC., Arai T, Bruce C, **Tall AR**. Receptors and lipid transfer proteins in HDL metabolism. *Ann N Y Acad Sci*. 2000 May;902:103-11.
165. **Tall AR**, Jiang XC, Luo Y, Silver D. 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. *Arterioscler Thromb Vasc Biol*. 2000 May;20(5):1185-8.
166. **Tall AR**, Schindler CW. A, B, C...gamma! *Arterioscler Thromb Vasc Biol*. 2000 Jun;20(6):1423-4.
167. Rubin EM, **Tall AR**. Perspectives for vascular genomics. *Nature*. 2000 Sep 14;407(6801):265-9.
168. Costet P, Luo Y, Wang N, **Tall AR**. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. *J Biol Chem*. 2000 Sep 8;275(36):28240-5.
169. Kawano K, Qin SC, Lin M, **Tall AR**, Jiang XC. Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions in vivo. *J Biol Chem*. 2000 Sep 22;275(38):29477-81.
170. **Tall AR**, Costet P, Luo Y. 'Orphans' meet cholesterol. *Nat Med*. 2000 Oct;6(10):1104-5.
171. Hope HR, Heuvelman D, Duffin K, Smith C, Zablocki J, Schilling R, Hegde S, Lee L, Witherbee B, Baganoff M, Bruce C, **Tall AR**, Krul E, Glenn K, Connolly DT. Inhibition of cholesteryl ester transfer protein by substituted dithiobisnicotinic acid dimethyl ester. Involvement of a critical cysteine. *J Lipid Res*. 2000 Oct;41(10):1604-1614.
172. Chen W, Silver DL, Smith JD, **Tall AR**. Scavenger receptor-BI inhibits ATP-binding cassette transporter 1- mediated cholesterol efflux in macrophages. *J Biol Chem*. 2000 Oct 6;275(40):30794-8000.



## Alan Richard Tall

173. Wang N, Silver DL, Costet P, **Tall AR**. Specific Binding of ApoA-I, Enhanced Cholesterol Efflux, and Altered Plasm Membrane Morphology in Cells Expressing ABC1. *J Biol Chem*. 2000 Oct 20;275(42):33053-58.
174. **Tall AR**, Wang N. Tangier Disease as a test of the Reverse Cholesterol transport hypothesis Commentary. *J. Clin. Invest*. 2000(10):1205-1207.
175. Lemaitre V, O'Byrne TK, Borczuk AC, Okada Y, **Tall AR**, D'Armiento J. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. *J Clin Invest*. 2001 May;107(10):1227-34.
176. Wang N, Silver, DL, Thiele C, **Tall AR**. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. *J. Biol. Chem*. 2001 Jun 29;276:23742-7.
177. Welch CL, Bretschger S, Latib N, Bezouevski M, Guo Y, Pleskac N, Liang C-P, Barlow C, Dansky H, Breslow JL, **Tall AR**. Localization of atherosclerosis susceptibility loci to chromosomes 4 and 6 using the *Ldlr* knockout mouse model. *PNAS*. 2001 Jul 3;98(14): 7946-51.
178. Silver DL, Wang N, Xiao X, **Tall AR**. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. *J Biol Chem*. 2001 Jul 6;276(27):25287-93.
179. Luo Y, Liang CP, **Tall AR**.: The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor. *J Biol Chem*. 2001 Jul 6;276(27):24767-73.
180. Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, **Tall AR**, Fruchart JC, Staels B, Lagrost L, Luc G: Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. *J. Biol. Chem*. 2001 Jul 13;276:25841-7.
181. Jiang, XC, Qin, S, Qiao, C, Kawano, K, Lin, M, Xiao, X, **Tall, AR**. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. *Nat. Med*. 2001 Jul;7(7):847-52.
182. Wang N, **Tall AR**. Therapeutic modulation of cellular cholesterol efflux. *Curr Atheroscler Rep*. 2001 Sep;3(5):345-7.
183. Silver DL, **Tall AR**. The cellular biology of scavenger receptor class B type I. *Curr Opin Lipidol*. 2001 Oct;12(5):497-504. Review.
184. **Tall AR**, Wang N, Mucksavage P. Is it time to modify the reverse cholesterol transport model? *J Clin Invest*. 2001 Nov;108(9):1273-5.
185. Chen W, Sun Y, Welch C, Gorelik A, Leventhal AR, Tabas I, **Tall, AR**. Preferential ATP-binding cassette transporter A1 (ABCA1)-mediated cholesterol efflux from late endosomes/lysosomes. *J.*

## Alan Richard Tall

Biol. Chem. 2001 Nov 23;276(47):43564-9.

186. Leventhal AR, Chen W, **Tall AR**, Tabas I. Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. *J. Biol. Chem.* 2001 Nov 30;276(9):1273-5.
187. Liang CP, **Tall AR**. Transcriptional profiling reveals global defects in energy metabolism, lipoprotein and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. *J. Biol. Chem.* 2001 Dec 28;276(52):49066-76.
188. **Tall AR**. Mighty mouse. *Circ Res.* 2002 Feb 22;90(3):244-5.
189. Weinberg RB, Anderson RA, Cook VR, Emmanuel F, Deneffe P, **Tall AR**, Steinmetz A. Interfacial exclusion pressure determines the ability of apolipoprotein A-IV truncation mutants to activate cholesterol ester transfer protein. *J. Biol. Chem.* 2002 Jun 14;277(24):21549-53.
190. Kako Y, Masse M, Huang LS, **Tall AR**, Goldberg IJ. Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. *J. Lipid Res.* 2002 Jun;43(6):872-7.
191. Gautier T, Masson D, Jong MC, Duverneuil L, Le Guern N, Deckert V, Pais De Barros JP, Dumont L, Bataille A, Zak Z, Jiang XC, **Tall AR**, Havekes LM, Lagrost. Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/apoCI-knocked out mice. *J. Biol. Chem.* 2002 Aug 30;277(35):31354-63.
192. Jiang XC, **Tall AR**, Qin S, Lin M, Schneider M, Lalanne F, Deckert V, Desrumaux C, Athias A, Witztum JL, Lagrost L. Phospholipid transfer protein (PLTP) deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. *J. Biol. Chem.* 2002 Aug 30;277(35):31850-6.
193. **Tall AR**, Costet P, Wang N. Regulation and mechanisms of macrophage cholesterol efflux. *J Clin Invest.* 2002 Oct;110(7):899-904.
194. **Tall AR**. Exercise to reduce cardiovascular risk - how much is enough? *N Engl J Med.* 2002 Nov 7;347(19):1522-4.
195. Wang N, Chen W, Linsel-Nitschke P, Martinez L, Agerholm-Larsen B, Silver DL, **Tall AR**. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. *J Clin Invest.* 2003 Jan;111(1):99-107.
196. Sun Y, Hao M, Luo Y, Liang CP, Silver DL, Cheng C, Maxfield FR, **Tall AR**. Stearoyl CoA desaturase inhibits ATP-binding cassette transporter A1-mediated cholesterol efflux and modulates membrane domain structure. *J Biol. Chem.* 2003 Feb 21;278(8):5813-20.
197. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, **Tall AR**. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. *ATVB* 2003 Feb 1;23(2):160-7. Review.

## Alan Richard Tall

198. **Tall AR.** ATVB in focus: Role of ABCA1 in cellular cholesterol efflux and reverse cholesterol transport. *ATVB* 2003 May 1; 23 (5):710-1. Editorial.
199. Wang N, **Tall AR.** Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. *ATVB* 2003 July;23(7);1178-1184.
200. Sun Y, Yao J, Kim TW, **Tall AR.** Expression of LXR target genes decreases cellular amyloid beta peptide secretion. *J Biol. Chem.* 2003 July 25;278(30):27688-94.
201. **Tall AR,** Lalanne F. Phospholipid transfer protein and atherosclerosis. *ATVB* 2003 Sep. 1;23(9):1484-5.
202. Martinez LO, Agerholm-Larsen B, Wang N, Chen W, **Tall AR.** Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. *J Biol. Chem.* 2003 Sep. 26;278(39):37368-74.
203. Wang N, Lan D, Gerbod-Giannone M, Linsel-Nitschke P, Jehle AW, Chen W, Martinez LO, **Tall AR.** ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipids but not cholesterol efflux. *J Biol. Chem.* 2003 Oct. 31;278(44):42906-12.
204. Costet P, Lalanne F, Gerbod-Giannone MC, Molina JR, Fu X, Lund EG, Gudas LJ, **Tall AR.** Retinoic acid receptor-mediated induction of ABAC1 in macrophages. *Mol. Cell Biol.* 2003 Nov.;23(21):7756-66.
205. Winkelmann BR, Hoffmann MM, Nauck M, Kumar AM, Nandabalan K, Judson RS, Boehm BO, **Tall AR,** Ruano G, Marz W. Haplotypes of the cheosteryl ester transfer protein gene predict lipid-modifying response to statin therapy. *Pharmacogenomics J.* 2003;3(5):284-96.
206. Masson D, Staels B, Gautier T, Desrumaux C, Athias A, Le Guern N, Schneider M, Zak Z, Dumont L, Deckert V, **Tall A,** Jiang XC, Lagrost L. Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. *J Lipid Res.* 2004 Mar;45(3):543-50.
207. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, **Tall AR.** Increased CD36 protein as a response to defective insulin signaling in macrophages. *J Clin Invest.* 2004 Mar;113(5):764-73.
208. **Tall AR.** C-reactive protein reassessed. *N Engl J Med.* 2004 Apr 1;350(14):1450-2.
209. Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, **Tall AR.** A prospective study of HDL cholesterol and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. *J Lipid Res* 2004 May;45 (5):948-53.
210. Wang N, Lan D, Chen W, Matsuura F, **Tall AR.** ATP-Binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. *PNAS.* 2004 June 29;101(6);9774-

## Alan Richard Tall

9779.

211. Li Y, Schwabe RF, Devries-Siemon T, Yao PM, Gerbod-Giannone MC, **Tall AR**, Davis RJ, Flavell R, Brenner DA, Tabas I. Free cholesterol-loaded macrophages are an abundant source of TNF-alpha and IL-6 Model of NF-kappa B- and MAP kinase-dependent inflammation in advanced atherosclerosis. *J Biol Chem*. 2005 Apr 11.
212. Seidelmann SB, De Luca C, Leibel RL, Breslow JL, **Tall AR**, Welch CL. Quantitative trait locus mapping of genetic modifiers of metabolic syndrome and atherosclerosis in LDL receptor deficient mice: identification of a locus for metabolic syndrome and increased atherosclerosis on mouse chromosome 4. *ATVB*. 2005 Jan;25(1):204-10.
213. Linsel-Nitschke P, Jehle AW, Shan J, Cao G, Bacic D, Lan D, Wang N, **Tall AR**. Potential role of ABCA7 in cellular lipid efflux to apoA-I. *J Lipid Res* 2005 Jan;46(1):86-92.
214. Linsel-Nitschke P, **Tall AR**. HDL as a target in the treatment of atherosclerotic cardiovascular disease. *Nat Rev Drug Discov*. 2005 Mar;4(3):193-205.
215. Desrumaux C, Risold PY, Schroeder H, Deckert V, Masson D, Athias A, Laplanche H, Le Guern N, Blache D, Jiang XC, **Tall AR**, Desor D, Lagrost L. Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice. *FASEB J*. 2005 Feb;19(2):296-7.
216. Li Y, Schwabe RF, DeVries-Seimon T, Yao PM, Gerbod-Giannone MC, **Tall AR**, Davis RJ, Flavell R, Brenner DA, Tabas I. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappaB- and map kinase-dependent inflammation in advanced atherosclerosis. *J Biol Chem*. 2005 Jun 10;280(23):21763-72.
217. Chen W, Wang N, **Tall AR**. A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes. *J Biol Chem*. 2005 Aug 12;280(32):29277-81.
218. Vikramadithyan RK, Hu Y, Noh HL, Liang CP, Hallam K, **Tall AR**, Ramasamy R, Goldberg IJ. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. *J Clin Invest*. 2005 Sept;115(9):2434-43.
219. Li Y, Gerbod-Giannone MC, Seitz H, Cui D, Thorp E, **Tall AR**, Matsushima GK, Tabas I. Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. *J Biol Chem*. 2006 Mar; 281(10): 6707-17.
220. Gerbod-Giannone MC, Li Y, Holleboom A, Han S, Hsu LC, Tabas I, **Tall AR**. TNFalpha induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells. *Proc Natl Acad Sci USA*. 2006 Feb; 103(9): 3112-7.
221. **Tall AR**. Protease variants, LDL, and coronary heart disease. *N Engl J Med*. 2006 Mar; 354(12): 1310-2.

## Alan Richard Tall

222. Wang N, Ranalletta M, Matuura F, Peng F, **Tall AR**. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. *Arterioscler Thromb Vasc Biol*. 2006 Jun; 26(6): 1310-6.
223. Han S, Liang CP, DeVries-Seimon T, Ranalletta M, Welch CL, Collins-Fletcher K, Accili D, Tabas I, **Tall AR**. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. *Cell Metab*. 2006 Apr ;3(4): 257-66.
224. Matsuura F, Wang N, Chen W, Jiang XC, **Tall AR**. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. *J Clin Invest*. 2006 May;116(5): 1435-42.
225. Zhou H, Li Z, Hojjati MR, Jang D, Beyer TP, Cao G, **Tall AR**, Jiang XC. Adipose tissue-specific CETP expression in mice: impact on plasma lipoprotein metabolism. *J Lipid Res*. 2006 Sep;47(9): 20011-9.
226. Jehle AW, Gardai SJ, Li S, Linsel-Nitschke P, Morimoto K, Janssen WJ, Vandivier RW, Wang N, Greenberg S, Dale BM, Qin C, Henson PM, **Tall AR**. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. *J Cell Biol*. 2006 Aug 14;174(4):547-56.
227. Ranalletta M, Wang N, Han S, Yvan-Charvet L, Welch C, **Tall AR**. Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with *Abcg1*<sup>-/-</sup> bone marrow. *Arterioscler Thromb Vasc Biol*. 2006 Oct; 26(10):2308-15.
228. Brar P, Kwon GY, Holleran S, Bai D, **Tall AR**, Ramakrishnan R, Green PH. Change in lipid profile in celiac disease: beneficial effect of gluten-free diet. *Am J Med*. 2006 Sep;119(9):786-90.